Result of AGM

RNS Number : 8190Q

Roquefort Therapeutics PLC

30 June 2022

 

30 June 2022

Roquefort Therapeutics plc

("Roquefort Therapeutics" or the "Company")

Results of AGM

Roquefort Therapeutics (LSE:ROQ), the Main Market listed biotech company focused on early-stage opportunities in the biotechnology sector, is pleased to announce that at the Company's Annual General Meeting ("AGM") held earlier today, all resolutions proposed were duly passed.

The resolutions were put to shareholders via a poll, the results of which were as follows:

Resolution		Poll Results
		For	Against	Abstain	Discretionary	Total
1	Shares	15,398,450	-	-	1,600,000	16,998,450
	%	90.59%	-	-	9.41%	100%
2	Shares	15,398,450	-	-	1,600,000	16,998,450
	%	90.59%	-	-	9.41%	100%
3	Shares	15,398,450	-	-	1,600,000	16,998,450
	%	90.59%	-	-	9.41%	100%
4	Shares	15,398,450	-	-	1,600,000	16,998,450
	%	90.59%	-	-	9.41%	100%
5	Shares	15,363,384	35,066	-	1,600,000	16,998,450
	%	90.38%	0.21%	-	9.41%	100%
6	Shares	15,398,450	-	-	1,600,000	16,998,450
	%	90.59%	-	-	9.41%	100%
7	Shares	15,398,450	-	-	1,600,000	16,998,450
	%	90.59%	-	-	9.41%	100%
8	Shares	15,398,450	-	-	1,600,000	16,998,450
	%	90.59%	-	-	9.41%	100%
9	Shares	15,363,384	35,066	-	1,600,000	16,998,450
	%	90.38%	0.21%	-	9.41%	100%
10	Shares	15,363,384	35,066	-	1,600,000	16,998,450
	%	90.38%	0.21%	-	9.41%	100%

The total number of ordinary shares in issue on 28 June 2022, the deadline for casting votes by proxy in advance of the AGM, was 71,900,000 shares.  23.64% of voting capital was instructed in respect of the resolutions put to the AGM.

 

Enquiries:

Roquefort Therapeutics plc Stephen West (Chairman) [phone] Buchanan (Public Relations) Ben Romney / Jamie Hooper / George Beale Optiva Securities Limited (Broker) [phone] Christian Dennis [phone]

For further information on Roquefort Therapeutics, please visit www.roquefortplc.com and @RoquefortTherap on Twitter.

LEI: ‎254900P4SISIWOR9RH34

About Roquefort Therapeutics

Roquefort Therapeutics (LSE:ROQ) is a Main Market listed biotech company developing products through the pre-clinical phase prior to partnering or selling to big pharma. The Company is a pre-clinical biotech company focused on developing first in class Midkine targeting drugs for the treatment of cancer.

Through extensive research resulting in validation through publication in over 1,000 scientific journals, Roquefort Therapeutics has identified the potential to exploit the broad therapeutic potential of Midkine for a number of clinical indications of unmet needs. Roquefort Therapeutics holds an exclusive licence to the largest global IP portfolio on Midkine. The Midkine blocking drug development markets have significant global market potential (in the multi-billion dollars). Roquefort Therapeutic's pre-clinical program is currently underway with an initial focus on cancer.

 

END

 

 

RAGSDDSUSEESEFM